Humoral and cellular capsid-specific immune responses to adeno-associated virus type 1 in randomized healthy donors

Journal of Immunology

Volumn 188, Issue 12, 2012, Pages 6418-6424

  Veron, Philippe ^a   Leborgne, Christian ^a   Monteilhet, Virginie ^a   Boutin, Sylvie ^a   Martin, Samia ^a   Moullier, Philippe ^a,b,c   Masurier, Carole ^a  

^a GÉNÉTHON   (France)

^b HÔTEL DIEU   (France)

^c UNIVERSITY OF FLORIDA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADENO ASSOCIATED VIRUS; ARTICLE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELLULAR IMMUNITY; CONTROLLED STUDY; EFFECTOR CELL; GENE THERAPY; GENE TRANSFER; GENETIC DISORDER; HUMAN; HUMORAL IMMUNITY; IMMUNE RESPONSE; INTERFERON PRODUCTION; NONHUMAN; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; SEROTYPE; T LYMPHOCYTE; VIRUS CAPSID; VIRUS REACTIVATION;

CAPSID PROTEINS; DEPENDOVIRUS; ENZYME-LINKED IMMUNOSORBENT ASSAY; FLOW CYTOMETRY; GENE THERAPY; GENETIC VECTORS; HUMANS; IMMUNITY, CELLULAR; IMMUNITY, HUMORAL; IMMUNOLOGIC MEMORY; RANDOM ALLOCATION; T-LYMPHOCYTES;

EID: 84862599629     PISSN: 00221767     EISSN: 15506606     Source Type: Journal    
DOI: 10.4049/jimmunol.1200620     Document Type: Article

References (32)

1. Kay, M. A., C. S. Manno, M. V. Ragni, P. J. Larson, L. B. Couto, A. McClelland, B. Glader, A. J. Chew, S. J. Tai, R. W. Herzog, et al. 2000. Evidence for gene transfer and expression of factor IX in haemophilia B patients treated with an AAV vector. Nat. Genet. 24: 257-261. (Pubitemid 30132193)
2. Manno, C. S., A. J. Chew, S. Hutchison, P. J. Larson, R. W. Herzog, V. R. Arruda, S. J. Tai, M. V. Ragni, A. Thompson, M. Ozelo, et al. 2003. AAVmediated factor IX gene transfer to skeletal muscle in patients with severe hemophilia B. Blood 101: 2963-2972. (Pubitemid 36857981)
3. Moss, R. B., D. Rodman, L. T. Spencer, M. L. Aitken, P. L. Zeitlin, D. Waltz, C. Milla, A. S. Brody, J. P. Clancy, B. Ramsey, et al. 2004. Repeated adenoassociated virus serotype 2 aerosol-mediated cystic fibrosis transmembrane regulator gene transfer to the lungs of patients with cystic fibrosis: a multicenter, double-blind, placebo-controlled trial. Chest 125: 509-521. (Pubitemid 38223630)
4. Nierman, M., J. Twisk, W. T. Hermens, D. Baker, S. Van Den Deventer, B. Rekke, J. J. Kastelein, E. Stroes, J. A. Kuivenhoven, and J. M. Meulenberg. 2007. Safety and efficacy of AMT-010, an adeno-associated virus based gene therapy vector administered to lipoprotein lipase-deficient subjects. Hum. Gene Ther. 18: 942.
5. Stroes, E. S., M. C. Nierman, J. J. Meulenberg, R. Franssen, J. Twisk, C. P. Henny, M. M. Maas, A. H. Zwinderman, C. Ross, E. Aronica, et al. 2008. Intramuscular administration of AAV1-lipoprotein lipase S447X lowers triglycerides in lipoprotein lipase-deficient patients. Arterioscler. Thromb. Vasc. Biol. 28: 2303-2304.
6. Murphy, S. L., H. Li, F. Mingozzi, D. E. Sabatino, D. J. Hui, S. A. Edmonson, and K. A. High. 2009. Diverse IgG subclass responses to adeno-associated virus infection and vector administration. J. Med. Virol. 81: 65-74.
7. Calcedo, R., L. H. Vandenberghe, G. Gao, J. Lin, and J. M. Wilson. 2009. Worldwide epidemiology of neutralizing antibodies to adeno-associated viruses. J. Infect. Dis. 199: 381-390.
8. Boutin, S., V. Monteilhet, P. Veron, C. Leborgne, O. Benveniste, M. F. Montus, and C. Masurier. 2010. Prevalence of serum IgG and neutralizing factors against adeno-associated virus (AAV) types 1, 2, 5, 6, 8, and 9 in the healthy population: implications for gene therapy using AAV vectors. Hum. Gene Ther. 21: 704-712.
9. Manno, C. S., G. F. Pierce, V. R. Arruda, B. Glader, M. Ragni, J. J. Rasko, M. C. Ozelo, K. Hoots, P. Blatt, B. Konkle, et al. 2006. Successful transduction of liver in hemophilia by AAV-factor IX and limitations imposed by the host immune response. Nat. Med. 12: 342-347. (Pubitemid 43355084)
10. Jiang, H., L. B. Couto, S. Patarroyo-White, T. Liu, D. Nagy, J. A. Vargas, S. Zhou, C. D. Scallan, J. Sommer, S. Vijay, et al. 2006. Effects of transient immunosuppression on adenoassociated, virus-mediated, liver-directed gene transfer in rhesus macaques and implications for human gene therapy. Blood 108: 3321-3328.
11. Scallan, C. D., H. Jiang, T. Liu, S. Patarroyo-White, J. M. Sommer, S. Zhou, L. B. Couto, and G. F. Pierce. 2006. Human immunoglobulin inhibits liver transduction by AAV vectors at low AAV2 neutralizing titers in SCID mice. Blood 107: 1810-1817. (Pubitemid 43289358)
12. + T-cell responses to adeno-associated virus capsid in humans. Nat. Med. 13: 419-422.
13. Mingozzi, F., J. Meulenberg, D. J. Hui, E. Basner-Tschakarajan, A. de Jong, P. Pos, and K. A. High. 2007. Capsid-specific T cell responses in humans upon intramuscular administration of an AAV-1 vector expressing LPLs447X transgene. Hum. Gene Ther. 18: 94.
14. Mingozzi, F., J. Meulenberg, D. J. Hui, E. Basner-Tschakarajan, A. de Jong, P. Pos, and K. A. High. 2007. Intramuscular administration of an AAV-1 vector in humans results in capsid-specific T cell-responses. Mol. Ther. 15: S403.
15. Mingozzi, F., J. J. Meulenberg, D. J. Hui, E. Basner-Tschakarjan, N. C. Hasbrouck, S. A. Edmonson, N. A. Hutnick, M. R. Betts, J. J. Kastelein, E. S. Stroes, and K. A. High. 2009. AAV-1-mediated gene transfer to skeletal muscle in humans results in dose-dependent activation of capsid-specific T cells. Blood 114: 2077-2086.
16. Li, H., M. O. Lasaro, B. Jia, S. W. Lin, L. H. Haut, K. A. High, and H. C. Ertl. 2011. Capsid-specific T-cell responses to natural infections with adenoassociated viruses in humans differ from those of nonhuman primates. Mol. Ther. 19: 2021-2030.
17. Gao, G., M. R. Alvira, S. Somanathan, Y. Lu, L. H. Vandenberghe, J. J. Rux, R. Calcedo, J. Sanmiguel, Z. Abbas, and J. M. Wilson. 2003. Adeno-associated viruses undergo substantial evolution in primates during natural infections. Proc. Natl. Acad. Sci. USA 100: 6081-6086. (Pubitemid 36576934)
18. Gao, G., L. H. Vandenberghe, M. R. Alvira, Y. Lu, R. Calcedo, X. Zhou, and J. M. Wilson. 2004. Clades of adeno-associated viruses are widely disseminated in human tissues. J. Virol. 78: 6381-6388. (Pubitemid 38715936)
19. Brantly, M. L., J. D. Chulay, L. Wang, C. Mueller, M. Humphries, L. T. Spencer, F. Rouhani, T. J. Conlon, R. Calcedo, M. R. Betts, et al. 2009. Sustained transgene expression despite T lymphocyte responses in a clinical trial of rAAV1-AAT gene therapy. Proc. Natl. Acad. Sci. USA 106: 16363-16368.
20. Flotte, T. R., B. C. Trapnell, M. Humphries, B. Carey, R. Calcedo, F. Rouhani, M. Campbell-Thompson, A. T. Yachnis, R. A. Sandhaus, N. G. McElvaney, et al. 2011. Phase 2 clinical trial of a recombinant adeno-associated viral vector expressing α1-antitrypsin: interim results. Hum. Gene Ther. 22: 1239-1247.
21. Mendell, J. R., L. R. Rodino-Klapac, X. Q. Rosales, B. D. Coley, G. Galloway, S. Lewis, V. Malik, C. Shilling, B. J. Byrne, T. Conlon, et al. 2010. Sustained α-sarcoglycan gene expression after gene transfer in limb-girdle muscular dystrophy, type 2D. Ann. Neurol. 68: 629-638.
22. Xiao, X., J. Li, and R. J. Samulski. 1998. Production of high-titer recombinant adeno-associated virus vectors in the absence of helper adenovirus. J. Virol. 72: 2224-2232. (Pubitemid 28100780)
23. Rivière, C., O. Danos, and A. M. Douar. 2006. Long-term expression and repeated administration of AAV type 1, 2 and 5 vectors in skeletal muscle of immunocompetent adult mice. Gene Ther. 13: 1300-1308. (Pubitemid 44264084)
24. Snyder, R. O., S. K. Spratt, C. Lagarde, D. Bohl, B. Kaspar, B. Sloan, L. K. Cohen, and O. Danos. 1997. Efficient and stable adeno-associated virus-mediated transduction in the skeletal muscle of adult immunocompetent mice. Hum. Gene Ther. 8: 1891-1900. (Pubitemid 27499662)
25. Charrier, S., L. Dupré, S. Scaramuzza, L. Jeanson-Leh, M. P. Blundell, O. Danos, F. Cattaneo, A. Aiuti, R. Eckenberg, A. J. Thrasher, et al. 2007. Lentiviral vectors targeting WASp expression to hematopoietic cells, efficiently transduce and correct cells from WAS patients. Gene Ther. 14: 415-428.
26. Herson, S., F. Hentati, A. Rigolet, A. Behin, N. B. Romero, F. Leturcq, P. Laforêt, T. Maisonobe, R. Amouri, H. Haddad, et al. 2012. A phase I trial of adeno-associated virus serotype 1-γ-sarcoglycan gene therapy for limb girdle muscular dystrophy type 2C. Brain 135: 483-492.
27. Monteilhet, V., S. Saheb, S. Boutin, C. Leborgne, P. Veron, M. F. Montus, P. Moullier, O. Benveniste, and C. Masurier. 2011. A 10 patient case report on the impact of plasmapheresis upon neutralizing factors against adeno-associated virus (AAV) types 1, 2, 6, and 8. Mol. Ther. 19: 2084-2091.
28. - (double negative) T cells: saviours or villains of the immune response? Biochem. Pharmacol. 82: 333-340.
29. Levy, J. A., J. N. Ihle, O. Oleszko, and R. D. Barnes. 1975. Virus-specific neutralization by a soluble non-immunoglobulin factor found naturally in normal mouse sera. Proc. Natl. Acad. Sci. USA 72: 5071-5075.
30. Nemerow, G. R., F. C. Jensen, and N. R. Cooper. 1982. Neutralization of Epstein-Barr virus by nonimmune human serum: role of cross-reacting antibody to herpes simplex virus and complement. J. Clin. Invest. 70: 1081-1091. (Pubitemid 13254932)
31. Harris, S. L., I. Frank, A. Yee, G. H. Cohen, R. J. Eisenberg, and H. M. Friedman. 1990. Glycoprotein C of herpes simplex virus type 1 prevents complement-mediated cell lysis and virus neutralization. J. Infect. Dis. 162: 331-337. (Pubitemid 20239944)
32. Ebenbichler, C. F., N. M. Thielens, R. Vornhagen, P. Marschang, G. J. Arlaud, and M. P. Dierich. 1991. Human immunodeficiency virus type 1 activates the classical pathway of complement by direct C1 binding through specific sites in the transmembrane glycoprotein gp41. J. Exp. Med. 174: 1417-1424.